 OutSourcing-Pharma.com | Lonza to Manufacture Heart Failure Enzyme Replacement Therapy Genetic Engineering News Lonza is to carry out GMP manufacture of Celladon's Phase IIb-stage targeted enzyme replacement therapy candidate Mydicar® (AAV1/SERCA2a) for clinical trials, and potentially for commercial supply. The viral vector-based treatment is designed to ... Lonza wins second high-tech trial supply contract in a week LONZA GROUP AG : Lonza and Celladon Corporation Announce Manufacturing ... Lonza and Celladon Announce Manufacturing Agreement for MYDICAR® |
